Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Net Income (2019 - 2025)

Historic Net Income for Benitec Biopharma (BNTC) over the last 7 years, with Q2 2025 value amounting to -$8.8 million.

  • Benitec Biopharma's Net Income fell 9010.37% to -$8.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$38.5 million, marking a year-over-year decrease of 7825.91%. This contributed to the annual value of -$38.5 million for FY2025, which is 7825.91% down from last year.
  • Benitec Biopharma's Net Income amounted to -$8.8 million in Q2 2025, which was down 9010.37% from -$14.5 million recorded in Q1 2025.
  • Over the past 5 years, Benitec Biopharma's Net Income peaked at -$3.5 million during Q1 2022, and registered a low of -$14.5 million during Q1 2025.
  • For the 5-year period, Benitec Biopharma's Net Income averaged around -$5.8 million, with its median value being -$4.8 million (2021).
  • Its Net Income has fluctuated over the past 5 years, first soared by 1178.57% in 2024, then crashed by 25010.86% in 2025.
  • Over the past 5 years, Benitec Biopharma's Net Income (Quarter) stood at -$4.8 million in 2021, then decreased by 15.95% to -$5.6 million in 2022, then decreased by 23.38% to -$6.9 million in 2023, then tumbled by 43.98% to -$10.0 million in 2024, then grew by 11.86% to -$8.8 million in 2025.
  • Its last three reported values are -$8.8 million in Q2 2025, -$14.5 million for Q1 2025, and -$10.0 million during Q4 2024.